17-alpha-Hydroxyprogesterone Caproate (17P, Makena) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial.

Trial Profile

17-alpha-Hydroxyprogesterone Caproate (17P, Makena) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 Oct 2014

At a glance

  • Drugs Hydroxyprogesterone (Primary)
  • Indications Preterm labour
  • Focus Therapeutic Use
  • Acronyms 17PinPROM
  • Most Recent Events

    • 05 Oct 2013 Planned end date changed from 1 Jan 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
    • 05 Jun 2012 Additional trial lead investigator identified as reported by ClinicalTrials.gov.
    • 15 Mar 2012 Planned End Date changed from 1 Jan 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top